Page 77 - பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் Today - Breaking & Trending Today

New Study Presents Evidence of Effectiveness and Safety Of Oleandrin and Phoenix Biotechnology's PBI-06150 Against SARS-CoV-2


Press release content from Business Wire. The AP news staff was not involved in its creation.
New Study Presents Evidence of Effectiveness and Safety Of Oleandrin and Phoenix Biotechnology’s PBI-06150 Against SARS-CoV-2
March 17, 2021 GMT
An article published last week in the
Journal of Biomedicine & Pharmacotherapy ( www.elsevier.com/locate/biopha; Vol 138 (2021) 111457) presents
in vitro evidence for significant inhibition of SARS-CoV-2 by oleandrin and a defined extract of
N. oleander (developed by Phoenix Biotechnology, Inc. and designated as PBI-06150), as well as
in vivo evidence of the safety and efficacy of PBI-06150.
ADVERTISEMENT
The
Journal of Biomedicine & Pharmacotherapy is an open access, peer-reviewed medical journal covering medical applications of pharmacology. It was established in 1956 and is published 10 times a year. ....

United States , San Antonio , University Of Texas , University Of Texas Md Anderson Cancer Center , University Of Texas Medical Branch , Phoenix Biotechnology Inc , Texas Biomedical Research Institute Biomed , Phoenix Biotechnology , Texas Medical Branch , Texas Biomedical Research Institute , Texas Biomed , Experimental Pharmacology , Cancer Center , Business Wire , Public Health , Products And Services , Coronavirus Pandemic , Product Testing , Diagnosis And Treatment , Severe Acute Respiratory Syndrome , Pharmaceutical Manufacturing , Health Care Industry , Lung Disease , Covid 19 Pandemic , Medical Research , Medical Biotechnology Industry ,

Helius Medical Technologies, Inc. Appoints Sherrie Perkins to its Board of Directors


Share:
NEWTOWN, Pa., March 17, 2021 (GLOBE NEWSWIRE) Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ( Helius or the Company ), a neurotech company focused on neurological wellness, today announced the appointment of Sherrie Perkins, effective March 15, 2021.
Ms. Perkins career history includes over 20 years of experience in the healthcare industry, including significant experience advising neuromodulation companies on their commercial and marketing activities, said Blane Walter, Chairman of Helius Board of Directors. We are pleased to expand our Board of Directors with the appointment of Ms. Perkins and look forward to leveraging her expertise and strategic insight as Helius prepares its next phase of market development activities. ....

United States , Sherrie Perkins , Blane Walter , Jack Powell , European Union Or Australia , University Of Texas Md Anderson Cancer Center , Helius Medical Technologies Inc , Venture Mentoring Service , Mississippi State University , Business Development Of Cyberonics Inc , Exchange Commission , Company Annual Report On Form , Toronto Stock Exchange , Central Michigan University , European Union , Therapeutic Goods Administration , Medical Technologies , Heliu Board , Helius Medical Technologies , Cancer Center , Vice President , New Business Development , Medical Technology , Central Michigan , Portable Neuromodulation Stimulator , Relations Contact ,